Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686609 | 0.83 | KCNN2 (0.41) | SMN1; SMN2TSHRALDH1A1HTTMAPT | |
| SCHEMBL21144248 | 0.79 | MAPT (0.49) | SMN1; SMN2TSHRALDH1A1HTTMAPT | |
| SCHEMBL19687487 | 0.74 | JAK3 (0.30) | — | |
| SCHEMBL19687387 | 0.69 | ALOX15 (0.44) | SMN1; SMN2MAPTLMNAGAAALOX15 | |
| SCHEMBL19686294 | 0.68 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRALDH1A1HTTMAPT | |
| SCHEMBL19687280 | 0.67 | KCNN2 (0.43) | SMN1; SMN2TSHRALDH1A1HTTMAPT | |
| SCHEMBL19686365 | 0.66 | IDH1 (0.48) | SMN1; SMN2TSHRMAPT | |
| SCHEMBL19686697 | 0.64 | ADORA2A (0.52) | SMN1; SMN2ALDH1A1HTTMAPTLMNA | |
| SCHEMBL19686984 | 0.64 | IDH1 (0.46) | SMN1; SMN2TSHRLMNAGAAALOX15 | |
| SCHEMBL31127339 | 0.64 | IDH1 (0.46) | SMN1; SMN2TSHRLMNAGAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| WO-2017139697-A9 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2017-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | SMN1; SMN2 1109/4885TSHR 2599/4885ALDH1A1 1320/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | SMN1; SMN2 1109/4885TSHR 2599/4885ALDH1A1 1320/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | SMN1; SMN2 1109/4885TSHR 2599/4885ALDH1A1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.